Skip to main content

Table 1 Patient demographics and genetics

From: D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial

 

Age at start (y)

gender

Pathogenic variant 1

Pathogenic variant 2

Reference (previous publications with the patient)

1

6

F

p.I120C

p.G228C

PMID: 28425223

   

c.359 T > C

c.682G > T

 

2

4

M

p.R141H

p.P113L

PMID: 10801058

   

c.442G > A

c.338C > T

 

3

5

F

p.S47L

p.Q33P

 
   

c.140C > T

c.98A > C

 

4

4

F

p.R141H

p.F183S

 
   

c.422G > A

c.548 T > C

 

5

17

M

p.R141H

p.F119L

PMID: 30293989

   

c.422G > A

c.357C > A

 

6

15

M

p.D188G

p.V231M

PMID: 30293989

   

c.563A > G

c.691G > A

 

7

19

M

p.T237R

p.C241S

PMID: 30293989

   

c.710C > G

c.722G > C

 

8

28

F

p.R141H

p.T81S

PMID: 17694350

   

c.422G > A

c.422G > A

 

9

2

M

p.R141H

p.F119L

 
   

c.422G > A

c.357C > A

 
  1. The variants shown are described using the NM_000303.2 transcript reference sequence